Top Markets
#1 ADO Protocol ADO Protocol +334.62%
#2 Islamic Coin Islamic Coin +155.44%
#3 Starpower Starpower +38.59%
#4 GoPlus Security GoPlus Security +36.89%
#5 GAIB AID GAIB AID +24.67%
#6 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +19.71%
#7 The Black Bull The Black Bull +11.74%
#8 Nockchain Nockchain +11.72%
#9 o1.exchange o1.exchange +11.53%
#10 Casper Network Casper Network +11.03%
Coin of the day
ADO Protocol ADO Protocol
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Caladrius Biosciences, Inc. Caladrius Biosciences, Inc.

Caladrius Biosciences, Inc.

CLBS
Classifica tra le azioni #33297
Caladrius Biosciences, Inc. operates as a clinical-stage biopharmaceutical... Caladrius Biosciences, Inc. operates as a clinical-stage biopharmaceutical company primarily engaged in the development and commercialization of cellular therapies. These therapies aim to either reverse various diseases or stimulate the regeneration of compromised tissue. The company's pipeline includes several key investigational therapies: HONEDRA, which has received the prestigious SAKIGAKE designation, is undergoing Phase II clinical trials as a potential treatment for critical limb ischemia; XOWNA is currently in Phase IIb trials targeting coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy, is being evaluated for chronic kidney disease in patients prior to requiring dialysis. Previously known as NeoStem, Inc., the firm adopted its current name, Caladrius Biosciences, Inc., in June 2015. Established in 1980, the company maintains its corporate headquarters in Basking Ridge, New Jersey.
Prezzo delle azioni
$0.4264
Ultima sincronizzazione: 2022-09-14
Capitalizzazione di mercato
$7.93M
Variazione (1 giorno)
-16.44%
Variazione (1 anno)
0.00%
Paese
US
Scambia Caladrius Biosciences, Inc. (CLBS)

Categoria

Healthcare
Ricavi di Caladrius Biosciences, Inc. (CLBS)
Ricavi nel Aug 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Caladrius Biosciences, Inc., i ricavi attuali dell'azienda (TTM) sono pari a 0. Nel 2026, l'azienda ha registrato ricavi di 0 uguale a i ricavi dell'anno 2026, che erano pari a 0. I ricavi rappresentano l'importo totale generato dalla vendita di beni o servizi. A differenza degli utili, le spese non vengono detratte.
Storico dei ricavi per Caladrius Biosciences, Inc. da 2026 a 2026
Ricavi alla fine di ogni anno
Anno Ricavi Cambia
Non abbastanza dati per le date fornite.
Ricavi di aziende simili o concorrenti
Azienda Ricavi Differenza nei ricavi Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE